Skip to main content
Download PDF

Association of MBL2 gene polymorphisms and MBL levels with dilated cardiomyopathy in a Chinese Han population

BMC Medical Genomics volume 17, Article number: 11 (2024) Cite this article

Abstract

Background

It has been reported that Mannose-binding lectin 2 (MBL2) gene polymorphisms and expression levels are related to dilated cardiomyopathy (DCM). This study aimed to investigate the potential association between MBL2 gene polymorphisms and the pathogenesis of DCM.

Methods

Five single nucleotide polymorphisms (SNPs) of the MBL2 gene were genotyped in 440 DCM patients and 532 controls in Southwest China. A luciferase reporter assay was used to detect the transcriptional activity the different genotypes. MBL serum levels, left ventricle ejection fraction (LVEF) and lower left ventricular end-diastolic diameter (LVEDD) were measured.

Results

The rs11003125 C allele increased the transcriptional activity of the MBL2 promoter compared with the rs11003125 G allele. The rs11003125 CC carriers had higher MBL serum levels, LVEF and LVEDD than the rs11003125 CG and GG carriers.

Conclusions

Our study first revealed that MBL2 polymorphisms and serum MBL levels were associated with DCM. Allele C in rs11003125 of MBL2 may upregulate the expression levels of MBL. High serum MBL levels may be a protective factor in DCM pathogenesis.

Peer Review reports

Introduction

Dilated cardiomyopathy (DCM) is a structural heart disease characterized by dilation and impaired contraction of the left ventricle or both ventricles, with a prevalence of up to 1:2500 in the general population [1]. It has been demonstrated that DCM is the third most common cause of heart failure and the most common condition requiring heart transplantation [2,3,4]. At present, the etiology of DCM is unclear [5]. Some evidence has shown that the occurrence of DCM is exacerbated by factors such as viral infection, inflammation, autoimmune diseases, toxic and metabolic damage, heredity, myocardial ischemia and tachycardia [5,6,7,8,9].

Mannose-binding lectin (MBL) is a protein found in plasma and is part of the innate immune system that can activate the complement cascade [10]. It is typically involved in antimicrobial and proinflammatory functions [11]. The level of the human MBL protein and its functionality are regulated mainly by single nucleotide polymorphisms (SNPs) of the MBL2 gene, which is located at chromosomal region 10q11.2-q21. The SNPs rs10082466, rs2120132, rs2099902, rs7096206 and rs11003125 in the MBL2 gene have been proven to be functionally important and deleterious to its structure and expression [12,13,14,15].

Some studies have shown that MBL2 SNPs in promoter and exonic regions regulate MBL serum levels in various autoimmune and infectious diseases [16,17,18,19]. MBL and the lectin complement pathway play important roles in vascular dysfunction, and cardiomyopathy has also been reported [20]. Considering that DCM is associated with factors such as myocardial inflammation, infection and immune responses and that MBL is related to these factors, we hypothesized that MBL2 polymorphisms and circulating MBL levels are associated with the occurrence of DCM. To test our hypothesis, a case‒control study was performed to evaluate polymorphisms of the MBL2 gene and serum MBL levels in DCM patients and healthy controls from a Chinese Han population living in Southwest China.

Materials and methods

Study subjects

This case‒control study enrolled 440 unrelated DCM patients from Sichuan Provincial People’s Hospital between January 2016 and December 2020. The clinical diagnosis was performed according to the revised criteria established by the 1995 WHO/International Society and Federation of Cardiology Task Force on the Classification of Cardiomyopathy (DCM group) [21]. The control group consisted of 532 subjects from a routine health survey. All subjects were Han Chinese living in Sichuan Province in southwest China. Patients with a history of hypertension, congenital heart disease, coronary heart disease, cardiac valve disease, tachyarrhythmia, heavy alcohol intake, acute viral myocarditis, systemic diseases of putative autoimmune origin or skeletal myopathies were intentionally excluded. The healthy controls also had no evidence of any organic cardiac diseases, hypertension, viral myocarditis, autoimmune diseases, heavy alcohol intake or skeletal myopathies. Echocardiography was performed to evaluate the left ventricular dimensions (left ventricular end-diastolic diameter, LVEDD) and left ventricular ejection fraction (LVEF) in all the subjects. The study protocol was reviewed and approved by the Ethics Committee of Sichuan Provincial People’s Hospital (No. 16,027), and all the subjects provided informed consent.

SNP selection and genotyping

Five SNPs (rs10082466, rs2120132, rs2099902, rs7096206, and rs11003125) were selected for our analysis according to a previous comprehensive study of the human MBL2 gene using in silico analysis [12].

EDTA-treated peripheral blood samples from all enrolled subjects were collected for genotyping. Genomic DNA was extracted from leukocytes by an extraction kit according to the manufacturer’s instructions (Bioteke Corporation, Beijing, China). The SNP genotyping work was performed using a custom-by design 48-Plex SNPscanTM Kit (Genesky Biotechnologies Inc., Shanghai, China) as previously described [22]. This technique was based on double ligation and multiplex fluorescence PCR. For quality control, approximately 4% of all samples were randomly selected for Sanger sequencing, and the results were 100% consistent.

Dual-luciferase reporter assay

A dual-luciferase reporter assay was used to detect the transcriptional activity of the different genotypes. The protocol has been described previously in detail [23]. A 748 bp DNA fragment in the MBL2 promoter containing the rs11003125 C or G genotype was synthesized by Sangon Corporation, inserted into the pGL3-basic vector and confirmed by Sanger sequencing. Five hundred nanograms of the pRL-TK vector and 500 ng of the pGL3-basic vector, pGL3-rs11003125 C vector or pGL3-rs11003125 G vector were transfected into human embryonic kidney 293 cells by Invitrogen Lipofectamine 3000 (Invitrogen, Waltham, Massachusetts, USA). Luciferase activity was measured at 48 h after transfection using the Promega Dual-Luciferase Reporter Assay System (Promega, Madison, Wisconsin, USA). The construction of each vector was tested in triplicate. The luciferase activity was computed with pGL3/pRL-TK.

Measurement of serum MBL levels

Serum MBL was obtained from the venous blood of 440 DCM patients and 532 healthy controls. The MBL concentration was measured with an enzyme-linked immunosorbent assay (ELISA) (Human MBL DuoSet, RD Systems, USA). All the measurements were performed in duplicate. Serum MBL levels were determined by a standard curve using mean optical density values.

Statistical analysis

Data analyses were conducted with SPSS 26.0 statistical software (SPSS, Inc., Chicago, IL, USA). The normality of continuous data was evaluated using the Shapiro‒Wilk and Kolmogorov‒Smirnov tests. Normally distributed data are expressed as the mean ± SD, and Student’s t test was applied. Nonnormally distributed data are expressed as the median and interquartile range (IQR), and the Kruskal‒Wallis test was applied. Pearson’s chi-square test was used for categorical variables in the comparison of Hardy-Weinberg equilibrium and allelic and genotypic frequencies in different groups. The Hardy-Weinberg equilibrium was tested for the patients and controls. SNPstats has been used to calculate genotypic associations in a case‒control pattern, assuming codominant, dominant, recessive, or overdominant genetic models [24]. Odds ratios (ORs) and 95% confidence intervals (CIs) were reported to evaluate the effects of any difference in allelic and genotypic distributions. A Bonferroni-corrected p-value of 0.01 was set to control for Type I errors. When the p-value was < 0.01, the differences in allele and genotype distributions were regarded as statistically significant between DCM patients and control subjects. When the p-value was less than 0.05 in other tests, the difference was regarded as statistically significant.

Results

Clinical data

The baseline characteristics of the DCM patients and controls are presented in Table 1. There were no significant differences between DCM patients and healthy controls in age and sex. DCM patients had statistically lower systolic blood pressure (SBP), diastolic blood pressure (DBP), and LVEF than the controls. Conversely, the LVEDD, heart rate and brain natriuretic peptide (BNP) level in patients with DCM were significantly higher than those in the control group. Serum MBL2 levels in DCM patients were much lower than those in controls (Fig. 1).

Table 1 Baseline characteristics of DCM patients and controls
Full size table
Fig. 1
figure 1

Distribution of serum MBL levels in DCM patients and controls

Full size image

Association between MBL2 polymorphisms and the risk of DCM

The genotype and allelic frequencies of the five SNPs (rs10082466, rs2120132, rs2099902, rs7096206, and rs11003125) between DCM patients and healthy controls are shown in Table 2. The rs10082466, rs2120132, rs2099902, rs7096206, and rs11003125 SNPs in DCM patients and control subjects were in Hardy-Weinberg equilibrium (p > 0.05). The p-values were 0.77 for rs10082466, 1.00 for rs2120132, 0.50 for rs2099902, 0.64 for rs7096206, and 0.07 for rs11003125, respectively. Significant differences in genotypes and allelic frequencies were found at rs11003125, indicating that this SNP might play an important role in the pathogenesis of DCM. As shown in Table 2, the rs11003125 polymorphism was associated with a predisposition to DCM according to the codominant (P = 0.007) and dominant (P = 0.002) models. The significant association between rs11003125 and DCM risk was confirmed by Bonferroni correction (corrected P = 0.01).

Table 2 Allele and genotype distributions of MBL2 genetic polymorphisms in DCM patients and controls
Full size table

Subjects with the CC genotype and C allele had a significantly lower risk of DCM than those with the GG genotype and G allele (CC versus GG, OR = 0.58, 95% CI = 0.40–0.84; C versus G, OR = 0.76, 95% CI = 0.63–0.91, P = 0.003). There was no significant association between rs10082466, rs7096206 or rs2099902 and DCM risk. Further analysis of the correlation between the rs11003125 genotype and clinical parameters determined via echocardiography was performed in our study. As shown in Fig. 2, the rs11003125 CC carriers had significantly higher LVEF than the rs11003125 CG (P < 0.001) and GG carriers (P < 0.001), and the rs11003125 CC carriers exhibited lower LVEDD than the rs1003125 CG (P < 0.001) and GG carriers (P = 0.003).

Fig. 2
figure 2

Distribution of LVEF (A) and LVEDD (B) in DCM patients stratified by rs11003125 genotype. □, interquartile ranges (IQRs).

Full size image

The rs11003125 C allele increased transcriptional activity

Plasmids containing the rs11003125 C or G allele were constructed, and reporter activity was measured to verify the influence of the rs11003125 polymorphism on the transcriptional activity of the MBL2 promoter. A schematic representation of the plasmid construction is shown in Fig. 3A. The pGL3-rs11003125 C and G vectors exhibited higher luciferase activity than the empty vector (Fig. 3B). The transcriptional activity of the MBL2 promoter was increased significantly by the pGL3-rs11003125 C vector compared with the pGL3-rs11003125 G vector (P = 0.022).

Fig. 3
figure 3

The rs11003125 C allele increased the transcriptional activity of the MBL2 promoter. A, Schematic representation of the constructed pGL3- rs11003125 C/G vector. B, The constructed vectors were transfected into human embryonic kidney 293 cells and luciferase activity was measured 48 h after transfection (P < 0.05)

Full size image

The rs11003125 CC genotype was associated with increased serum MBL levels

To determine whether rs11003125 influenced MBL expression, we analyzed the serum MBL levels in DCM patients who were stratified by rs11003125 genotype. The results revealed that the median MBL levels of the rs11003125 CC, CG and GG carriers were 1924.00 ng/ml (IQRs: 1611.00-2462.00), 1263.00 ng/ml (IQRs: 962.25-1518.25) and 1132.00 ng/ml (IQRs: 757.50–1554.00), respectively. The rs11003125 CC carriers had significantly increased serum MBL levels compared to the rs11003125 CG (P < 0.001) and GG carriers (P < 0.001) (Fig. 4).

Fig. 4
figure 4

Distribution of serum MBL levels in DCM patients stratified by rs11003125 genotype. □, interquartile ranges (IQRs).

Full size image

Discussion

This study provides the first evidence that a polymorphism in the MBL2 gene (rs11003125) is significantly associated with Chinese Han DCM patients living in Southwest China. The expression levels of MBL were upregulated in DCM patients carrying the rs11003125 CC genotype compared with those carrying the rs11003125 GG or GC genotype. Moreover, the rs11003125 C allele increased the transcriptional activity of the MBL2 promoter in contrast with the rs11003125 G allele. The results showed that the rs11003125 CC genotype and C allele are strongly associated with a reduced risk of DCM. In other words, the rs11003125 GG genotype and G allele significantly elevated the risk of DCM.

The pathogenesis of DCM is not fully understood. Infection, inflammation and autoimmunity are involved in the progression of the disease. Disturbance of the immune system is often reported to be associated with DCM. Myocardial inflammation is one of the most common mechanisms in DCM [25]. MBL deficiency is related to susceptibility to autoimmune diseases, and serum MBL levels vary remarkably due to the variant alleles in the MBL2 gene [26]. Previous studies have shown that the absence of MBL affects the occurrence of cardiovascular complications and myocardial ischemia [27, 28]. Similarly, downregulation of MBL in DCM was found in our study, suggesting that MBL may be involved in the pathogenesis of DCM. However, not all individuals with downregulated MBLs suffer from DCM. This phenomenon suggested that gene polymorphisms might play a role in these processes.

The influence of MBL2 gene polymorphisms on human diseases has been reported in many studies. Kim SH et al. investigated three SNPs (rs11003125, rs11003124, rs7096206) in the MBL2 promoter and found that polymorphisms of the MBL2 gene increased susceptibility to the development of diisocyanate-induced occupational asthma [29]. Mokhtari MJ et al. demonstrated that MBL2 gene polymorphisms were associated with dental caries in Iranian adults and that the GG and GC genotypes of the MBL2 rs11003125 polymorphism remarkably increased caries risk according to the dominant model [30]. Zhang N et al. showed that the rs1800450 and rs11003125 SNPs of the MBL2 gene had strong linkage disequilibrium and were associated with type 2 diabetes in the North Chinese Han population [14]. Subjects with the CC genotype of rs11003125 had much higher serum MBL levels. Moreover, Yokoyama E and colleagues proved that the MBL2 rs11003125 GG or GC genotype was significantly associated with patients with cystic fibrosis as a risk factor [31]. Our study showed that the rs11003125 CC genotype and C allele of MBL2 were associated with a decreased risk of DCM, suggesting that G increases susceptibility while C offers protection. The results were consistent with the above previous studies.

According to the literature, rs11003125 located in the MBL2 promoter and SNPs in the promoter of a gene were supposed to influence its expression level [32, 33]. Thus, we investigated the relationship of rs11003125 with the expression levels of MBL. The results showed that the rs11003125 CC genotype was related to higher expression levels of MBL than the GG and GC genotypes. Analogously, MBL levels of the rs11003125 CC group in diabetic nephropathy [14], sepsis and common infectious diseases were also found to be significantly higher [34, 35]. The results of a luciferase reporter assay suggested that the rs11003125 C allele increased the transcriptional activity of the MBL2 promoter. Previous in silico analysis revealed that rs11003125 is located at the binding site of the transcription factor in the MBL2 gene [12]. The change from allele G to allele C might increase the motif score or the binding efficiency between transcription factors and the binding site. Our findings implied that the rs11003125 C allele increased the transcriptional activity of the MBL2 promoter by upregulating the binding efficiency between transcription factors and the binding site. This study provided evidence that CC carriers with DCM at the rs11003125 polymorphism were related to two important clinical parameters of cardiac function, LVEF and LVEDD. DCM patients with the rs11003125 CC genotype had much higher LVEF and lower LVEDD than the other genotype carriers. This result revealed that genotypic variations might be prognostic factors for DCM. The above evidence suggested that rs11003125 might play a protective role in the development of DCM by increasing the transcriptional activity of the MBL2 promoter and MBL expression.

Conclusion

Our findings demonstrated that MBL2 polymorphisms and circulating MBL levels are associated with the occurrence of DCM. High serum MBL levels may be a protective factor in DCM pathogenesis, and the C allele of MBL2 rs11003125 may upregulate the expression of MBL by increasing the transcriptional activity of the MBL2 promoter.

Data availability

The datasets used and/or analyzed during the current study are available from https://weibo.com/u/5672759868?tabtype=album&uid=5672759868&index=0.

References

  1. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB, American Heart HF, Council on Clinical Cardiology C, Transplantation C, Quality of R, Outcomes G, Functional G, Translational Biology Interdisciplinary Working E. Council on, Prevention, Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention, Circulation. 2006;113(14):1807–16.

  2. Tsirka AE, Trinkaus K, Chen SC, Lipshultz SE, Towbin JA, Colan SD, Exil V, Strauss AW, Canter CE. Improved outcomes of pediatric dilated cardiomyopathy with utilization of heart transplantation. J Am Coll Cardiol. 2004;44(2):391–7.

    Article  PubMed  Google Scholar 

  3. Jefferies JL, Towbin JA. Dilated cardiomyopathy. Lancet. 2010;375(9716):752–62.

    Article  PubMed  Google Scholar 

  4. Halliday BP, Cleland JGF, Goldberger JJ, Prasad SK. Personalizing risk stratification for Sudden Death in Dilated Cardiomyopathy: the past, Present, and Future. Circulation. 2017;136(2):215–31.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, Baughman KL, Kasper EK. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342(15):1077–84.

    Article  CAS  PubMed  Google Scholar 

  6. Watkins H, Ashrafian H, Redwood C. Inherited cardiomyopathies. N Engl J Med. 2011;364(17):1643–56.

    Article  CAS  PubMed  Google Scholar 

  7. Hazebroek M, Dennert R, Heymans S. Idiopathic dilated cardiomyopathy: possible triggers and treatment strategies. Neth Heart J. 2012;20(7–8):332–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Gan T, Hu J, Aledan AKO, Liu W, Li C, Lu S, Wang Y, Xu Q, Wang Y, Wang Z. Exploring the pathogenesis and immune infiltration in dilated cardiomyopathy complicated with atrial fibrillation by bioinformatics analysis. Front Immunol. 2023;14:1049351.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Jain A, Norton N, Bruno KA, Cooper LT Jr., Atwal PS, Fairweather D. Sex differences, Genetic and Environmental Influences on Dilated Cardiomyopathy. J Clin Med 10(11) (2021).

  10. Tsutsumi A, Takahashi R, Sumida T. Mannose binding lectin: genetics and autoimmune Disease. Autoimmun Rev. 2005;4(6):364–72.

    Article  CAS  PubMed  Google Scholar 

  11. Ip WK, Takahashi K, Ezekowitz RA, Stuart LM. Mannose-binding lectin and innate immunity. Immunol Rev. 2009;230(1):9–21.

    Article  PubMed  Google Scholar 

  12. Kalia N, Sharma A, Kaur M, Kamboj SS, Singh J. A comprehensive in silico analysis of non-synonymous and regulatory SNPs of human MBL2 gene. Springerplus. 2016;5(1):811.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Cao Y, Wang X, Cao Z, Wu C, Wu D, Cheng X. Genetic polymorphisms of MBL2 and Tuberculosis susceptibility: a meta-analysis of 22 case-control studies. Arch Med Sci. 2018;14(6):1212–32.

    Article  CAS  PubMed  Google Scholar 

  14. Zhang N, Zhuang M, Ma A, Wang G, Cheng P, Yang Y, Wang X, Zhang J, Chen X, Lu M. Association of levels of mannose-binding lectin and the MBL2 gene with type 2 Diabetes and diabetic Nephropathy. PLoS ONE. 2013;8(12):e83059.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Zanetti KA, Haznadar M, Welsh JA, Robles AI, Ryan BM, McClary AC, Bowman ED, Goodman JE, Bernig T, Chanock SJ. Harris, 3’-UTR and functional secretor haplotypes in mannose-binding lectin 2 are associated with increased colon Cancer risk in African americans. Cancer Res. 2012;72(6):1467–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Jack DL, Turner MW. Anti-microbial activities of mannose-binding lectin. Biochem Soc Trans. 2003;31(Pt 4):753–7.

    Article  CAS  PubMed  Google Scholar 

  17. Martiny FL, Veit TD, Brenol CV, Brenol JC, Xavier RM, Bogo MR, Chies JA. Mannose-binding lectin gene polymorphisms in Brazilian patients with rheumatoid arthritis. J Rheumatol. 2012;39(1):6–9.

    Article  CAS  PubMed  Google Scholar 

  18. Eisen DP. Mannose-binding lectin deficiency and respiratory tract Infection. J Innate Immun. 2010;2(2):114–22.

    Article  CAS  PubMed  Google Scholar 

  19. Chalmers JD, McHugh BJ, Doherty C, Smith MP, Govan JR, Kilpatrick DC, Hill AT. Mannose-binding lectin deficiency and Disease severity in non-cystic fibrosis bronchiectasis: a prospective study. Lancet Respir Med. 2013;1(3):224–32.

    Article  CAS  PubMed  Google Scholar 

  20. Pavlov VI, La Bonte LR, Baldwin WM, Markiewski MM, Lambris JD, Stahl GL. Absence of mannose-binding lectin prevents hyperglycemic cardiovascular Complications. Am J Pathol. 2012;180(1):104–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O’Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation. 1996;93(5):841–2.

    Article  CAS  PubMed  Google Scholar 

  22. Chen X, Li S, Yang Y, Yang X, Liu Y, Liu Y, Hu W, Jin L, Wang X. Genome-wide association study validation identifies novel loci for atherosclerotic Cardiovascular Disease. J Thromb Haemost. 2012;10(8):1508–14.

    Article  CAS  PubMed  Google Scholar 

  23. Wei G, Liao C, Jian C, Liang L, Liu J, Tang Y, Wei Y. Evaluation of miR-34b/c polymorphisms to the risk of ischemic Stroke. J Hypertens. 2020;38(8):1481–7.

    Article  CAS  PubMed  Google Scholar 

  24. Sole X, Guino E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006;22(15):1928–9.

    Article  CAS  PubMed  Google Scholar 

  25. Maisch B, Richter A, Sandmoller A, Portig I, Pankuweit S, Network BM-HF. Inflammatory dilated cardiomyopathy (DCMI). Herz. 2005;30(6):535–44.

    Article  PubMed  Google Scholar 

  26. Worthley DL, Bardy PG, Mullighan CG. Mannose-binding lectin: biology and clinical implications. Intern Med J. 2005;35(9):548–55.

    Article  CAS  PubMed  Google Scholar 

  27. Zou C, La Bonte LR, Pavlov VI, Stahl GL. Murine hyperglycemic vasculopathy and cardiomyopathy: whole-genome gene expression analysis predicts cellular targets and regulatory networks influenced by mannose binding lectin. Front Immunol. 2012;3(15).

  28. Busche MN, Walsh MC, McMullen ME, Guikema BJ, Stahl GL. Mannose-binding lectin plays a critical role in myocardial ischaemia and reperfusion injury in a mouse model of Diabetes. Diabetologia. 2008;51(8):1544–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Kim SH, Bae SJ, Palikhe S, Ye YM, Park HS. Effects of MBL2 polymorphisms in patients with diisocyanate-induced occupational Asthma. Exp Mol Med. 2015;47:e157.

    Article  CAS  PubMed  Google Scholar 

  30. Mokhtari MJ, Koohpeima F, Hashemi-Gorji F. Association of the Risk of Dental Caries and Polymorphism of MBL2 rs11003125 gene in Iranian adults. Caries Res. 2019;53(1):60–4.

    Article  CAS  PubMed  Google Scholar 

  31. Yokoyama E, Chavez-Saldana M, Orozco L, Cuevas F, Lezana JL, Vigueras-Villasenor RM, Rojas-Castaneda JC, Landero DA. Influence of SNPs in genes that modulate Lung Disease Severity in a group of Mexican patients with cystic fibrosis. Arch Med Res. 2018;49(1):18–26.

    Article  CAS  PubMed  Google Scholar 

  32. Alipour A, Cabezas MC, Elte JW, Vallve JC, Ribalta J, Zwinderman AH, Defesche JC, Jukema JW. Mannose binding lectin 2 haplotypes do not affect the progression of coronary Atherosclerosis in men with proven coronary artery Disease treated with pravastatin. Atherosclerosis. 2011;215(1):125–9.

    Article  CAS  PubMed  Google Scholar 

  33. Ferraroni NR, Segat L, Guimaraes RL, Brandao LA, Crovella S, Constantino-Silva RN, Loja C, da Silva Duarte AJ, Grumach AS. Mannose-binding lectin and MBL-associated serine protease-2 gene polymorphisms in a Brazilian population from Rio De Janeiro. Int J Immunogenet. 2012;39(1):32–8.

    Article  CAS  PubMed  Google Scholar 

  34. Huh JW, Song K, Yum JS, Hong SB, Lim CM, Koh Y. Association of mannose-binding lectin-2 genotype and serum levels with prognosis of sepsis. Crit Care. 2009;13(6):R176.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Weintraub RG, Semsarian C, Macdonald P. Dilated cardiomyopathy. Lancet. 2017;390(10092):400–14.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors are very grateful to our patients and healthy volunteers for their blood donations and agreement to participate in this study. We extend our sincere gratitude to Mr. Wentao Xu for his invaluable technical support and assistance throughout the trial phase of our research.

Funding

This work is supported by the Foundation of Science and Technology Department of Sichuan Province (No. 2019YFS0249 and No. 22NSFSC1165), the Natural Science Foundation of Sichuan (No. 2023NSFSC0590), and the National Natural Science Foundation of China (No. 82003376, No. 82200767 and No. 81600259).

Author information

Author notes

  1. Yujie Mao and Hong Wei contributed equally to this work.

Authors and Affiliations

  1. Institute of Dermatology and Venereology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China

    Yujie Mao & Yugang Gong

  2. Department of Ophthalmology and Vision Research Laboratory, West China Hospital, Sichuan University, Chengdu, China

    Hong Wei

  3. Department of Nephrology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China

    Lei Peng

  4. Department of Cardiology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China

    Yu Chen

Authors
  1. Yujie Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hong Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yugang Gong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lei Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yu Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YM and YC conceived and designed the experiments. YM, YG, LP and YC performed the experiments. LP, YG performed the statistical analysis. LP and YC contributed to patient recruitment and clinical characteristics. YM, YG, LP and YC contributed to control recruitment. YM wrote the original draft. LP and YC performed writing-review and editing. YM, YG and YC provided financial support. All authors contributed to the article and approved the submitted version.

Corresponding authors

Correspondence to Lei Peng or Yu Chen.

Ethics declarations

Ethics approval and consent to participate

The study protocol was reviewed and approved by the Ethics Committee of Sichuan Provincial People’s Hospital, and all the subjects provided informed consent.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mao, Y., Wei, H., Gong, Y. et al. Association of MBL2 gene polymorphisms and MBL levels with dilated cardiomyopathy in a Chinese Han population. BMC Med Genomics 17, 11 (2024). https://doi.org/10.1186/s12920-023-01787-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12920-023-01787-2

Keywords

BMC Medical Genomics

ISSN: 1755-8794

Contact us